Chikungunya Virus Clinical Trial
Official title:
A Phase 3 Safety and Immunogenicity Trial of the VLP-Based Chikungunya Virus Vaccine PXVX0317 in Adults ≥65 Years of Age
The purpose of this phase 3, randomized, double-blind, placebo-controlled study is to evaluate the safety and immunogenicity to PXVX0317 in adults ≥65 years of age.
Co-primary Objectives: - To compare the anti-CHIKV serum neutralizing antibody (SNA) response to PXVX0317 and placebo at Day 22, as measured by geometric mean titer (GMT) and clinically relevant difference in seroresponse rate (PXVX0317 minus placebo) in adults ≥65 years of age. - To evaluate the safety of PXVX0317 in adults ≥65 years of age Secondary Objectives: - To compare the anti-CHIKV SNA response to PXVX0317 and placebo at Day 15 and Day 183, as measured by GMT and seroresponse rate. - To compare the anti-CHIKV SNA response to PXVX0317 and placebo in participants ≥65 to <75 and ≥75 years of age as measured by GMT and seroresponse rate. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05072080 -
A Phase 3 Trial of the VLP-Based Chikungunya Vaccine PXVX0317
|
Phase 3 | |
| Completed |
NCT05065983 -
A Study to Assess the Safety and Immunogenicity of PXVX0317 Chikungunya Virus Virus-Like Particle Vaccine
|
Phase 2 | |
| Terminated |
NCT00391313 -
CuraChik : A Trial of the Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease
|
Phase 3 | |
| Completed |
NCT02305732 -
A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components
|
||
| Completed |
NCT01489358 -
Chikungunya Virus Vaccine Trial in Healthy Adults
|
Phase 1 | |
| Completed |
NCT03325075 -
Safety, Tolerability, and Immunogenicity of VAL-181388 in Healthy Subjects
|
Phase 1 |